Colchicine Administered in the First Episode of Acute Idiopathic Pericarditis: A Randomized Multicenter Open-label...

Area of Science:

• Cardiology
• Internal Medicine
• Pharmacology

Background:

• Acute idiopathic pericarditis (AIP) recurrence is a clinical challenge.
• Limited data exists on colchicine's benefit in first-episode AIP without corticosteroid use.
• Understanding optimal treatment for AIP is crucial for patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of colchicine in preventing recurrent pericarditis in patients experiencing their first AIP episode.
• To assess if adding colchicine to conventional anti-inflammatory drugs impacts recurrence rates compared to conventional treatment alone.
• To determine the effect of colchicine on the time to first pericarditis recurrence in this specific patient group.

Main Methods:

• A randomized, multicenter, open-label study design was employed.
• Patients with first-episode AIP (excluding secondary causes) were randomized into two groups.
• Group A received conventional anti-inflammatory treatment plus colchicine (3 months); Group B received conventional treatment only. Corticosteroids were excluded.

Main Results:

• 110 patients (83.6% male, mean age 44 years) were randomized.
• No significant difference in recurrent pericarditis rates was observed between the colchicine group (13.5%) and the control group (7.8%; P=.34).
• The time to first recurrence also did not differ significantly between the two groups (9.6 months vs. 8.3 months; P=.80).

Conclusions:

• In first-episode AIP patients not treated with corticosteroids, adding colchicine to conventional anti-inflammatory therapy did not reduce the rate of recurrent pericarditis.
• The findings suggest colchicine may not be beneficial for preventing recurrence in this specific AIP population.
• Further research may be needed to clarify colchicine's role in different AIP contexts.